Risedronate therapy prevents corticosteroid-induced bone loss: A twelve- month, multicenter, randomized, double-blind, placebo-controlled, parallel- group study

Arthritis and Rheumatism

Volumn 42, Issue 11, 1999, Pages 2309-2318

  Cohen, Stanley ^a   Levy, Robert M ^b   Keller, Michael ^h   Boling, Eugene ^h   Emkey, Ronald D ^c   Greenwald, Maria ^h   Zizic, Thomas M ^h   Wallach, Stanley ^d   Sewell, Kathryn L ^e   Lukert, Barbara P ^f   Axelrod, Douglas W ^g   Chines, Arkadi A ^g  

^a METROPLEX CLINICAL RESEARCH CENTER   (United States)

^b Olympia Osteoporosis Center   (United States)

^c READING HOSPITAL AND MEDICAL CENTER   (United States)

^d NYU HOSPITAL FOR JOINT DISEASES   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^g PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^h Metroplex Clinical Research Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE RESORPTION; CALCIUM CHANNEL BLOCKERS; DEMOGRAPHY; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 0033498501     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K     Document Type: Article

References (38)

1. Haynes RC Jr, Gilman AE, Rail TW, Nies AS, Taylor P, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: McGraw-Hill; 1990.
2. Lukert BP. Glucocorticoid-induced osteoporosis. South Med J 1992;85 Suppl 2:48-51.
3. Bressot C, Meunier PJ, Chapuy MC, Lejeune E, Edouard C, Darby AJ. Histomorphometric profile, pathophysiology, and reversibility of glucocorticosteroid-induced osteoporosis. Metab Bone Dis Rel Res 1979;1:303-11.
4. Dempster DW, Ariot MA, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in glucocortico-steroid-induced osteoporosis. Calcif Tissue Int 1983;35:410-7.
5. Jec WSS, Park HZ, Roberts WE, Kenner GH. Glucocorticosteroid and bone. Am J Anat 1970;129:477-9.
6. Nordin BEC, Marshall DH, Francis RM, Crilly RG. The effects of sex steroid and corticosteroid hormones on bone. J Steroid Biochem 1981;15:171-4.
7. Klein RG, Arnaud SB, Gallagher JC. Intestinal calcium absorption in exogenous hypercortisonism. J Clin Invest 1977;60:253-9.
8. Reid IR. Steroid osteoporosis. Calcif Tissue Int 1989;45:63-7.
9. Crilly RG, Cawood M, Marshall DH, Nordin BEC. Hormonal status in normal, osteoporotic and corticosteroid-treated post-menopausal women. J R Soc Med 1978;71:733-6.
10. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving chronic glucocorticoid therapy. Arch Intern Med 1990;150:2545-8.
11. Hall GM, Spector TD, Griffin AJ, Jawad ASM, Hall ML, Doyle DV. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 1993; 36:1510-6.
12. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss: a longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983;25:615-20.
13. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
14. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-23.
15. Verstraeten A, Dequeker J. Risk of vertebral fracture in women with rheumatoid arthritis. Ann Rheum Dis 1986;45:852-7.
16. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, et al. Vitamin D and calcium in the prevention of corticosteroid-induced osteoporosis - a 3 year follow-up. J Rheumatol 1996;23:995-1000.
17. Adams JS, Wahl TO, Lukert BP. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism 1981;30:217-21.
18. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992;7:1063-9.
19. Rizzato G, Tosi G, Schiraldi G, Montemurro L, Zanni D, Sisti S. Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis. Sarcoidosis 1988;5:99-103.
20. Luengo M, Picado C, Del Rio L, Guanabens M, Montserrat IM, Setoain J. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. Am Rev Respir Dis 1990;142: 104-7.
21. Rizzoli R, Chevalley T, Spector TD, Bonjour JP. Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporos Int 1995;5: 39-46.
22. Guaydier-Souquieres G, Kotzki PO, Sabatier JP, Bassecathalinat B, Loeb G. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density - a double-masked randomized study. Osteoporos Int 1996;6:171-7.
23. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
24. Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995;98:459-63.
25. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994;33:348-50.
26. Skingle SJ, Moore DJ, Crisp AJ. Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy. Int J Clin Pract 1997;51:364-7.
27. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339: 292-9.
28. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39: 1791-801.
29. Eastell R. Management of corticosteroid-induced osteoporosis. J Intern Med 1995;237:439-47.
30. Reid IR. Glucocorticoid osteoporosis-mechanisms and management. Eur J Endocrinol 1997;137:209-17.
31. Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 1994;9:503-14.
32. Melton LJ III, Lane AW, Eastell R, O'Fallon WM, Riggs BL. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993;3:113-9.
33. Eriksen EF, Steiniche T, Mosekilde L, Melsen F. Histomorphometric analysis of bone in metabolic bone disease. Endocrinol Metab Clin North Am 1989;18:919-54.
34. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, et al. Prevention of corticosteroid osteoporosis - a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52.
35. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 1996;23:995-1000.
36. Amin S, LaValley MP, Simms RW, Felson DT. A meta-analysis ranking efficacy of treatments for corticosteroid-induced osteoporosis [abstract]. Arthritis Rheum 1998;41 Suppl 9:S137.
37. Seibel MJ, Baylink DJ, Farley JR, Epstein S, Yamauchi M, Eastell R, et al. Basic science and clinical utility of biochemical markers of bone turnover - a congress report. Exp Clin Endocrinol Diabetes 1997;105:125-33.
38. Dolan AL, Moniz C, Dasgupta B, Li F, Mackintosh C, Todd P, et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997;40: 2022-9.